Drug Safety EU


Drug safety must continue to evolve to meet heightened patient expectations and the fluctuating regulatory climate. It is becoming critical to exploit opportunities offered by emerging technologies, big data and personalised healthcare. To succeed in this new environment, we need to assess the regulatory updates; we need to examine how to implement regulations strategically and operationally in addition to discussing ways to ensure transparency in drug safety. Managing multiple stakeholders successfully is key – integrating patients, physicians, drug manufacturers, regulators and consumers together will enable industry and partners to devise effective drug safety strategies and decisions going forward.

The 10th World Drug Safety Congress Europe 2016 will bring together industry pioneers to explore global challenges in drug safety. This is your opportunity to engage and sit alongside key opinion leaders who are bucking industry trends in pharmacovigilance.

Who should attend? 

Heads of:

  • Pharmacovigilance
  • Drug Safety
  • Risk Management
  • QPPV
  • Patient Safety
  • Safety Surveillance
  • Post authorisation safety
  • Pharmacoepidemiology
  • Clinical Safety

 Why attend?

  • Hear updates from key agencies including MHRA and PRAC
  • Explore strategies for best practice in benefit-risk management
  • Discover the building blocks for a proactive drug safety culture
  • Assess how to manage continued challenges in the European pharmacovigilance legislation
  • Gain fresh insights into requirements and the future of drug safety